ORIC的蛋zertinib在NSCLC病人的HER2或EGFR突变中显示出强有力的结果,导致选定剂量用于今后的试验。 ORIC's enozertinib showed strong results in NSCLC patients with HER2 or EGFR mutations, leading to a selected dose for future trials.

ORIC制药公司报告说,在以前治疗过的有HER2前20突变的NSCLC病人中,第1b阶段的Enozertinib试验结果显示35%的客观反应率和100%的疾病控制率,每天为80毫克,主要是轻微副作用。 ORIC Pharmaceuticals reported Phase 1b trial results for enozertinib in previously treated NSCLC patients with HER2 exon 20 mutations, showing a 35% objective response rate and 100% disease control rate at 80 mg daily, with mostly mild side effects. 根据耐受性和有效性,为今后第一线开发选择了80毫克剂量,而没有计划为HER2组进行进一步开发。 The 80 mg dose was selected for future first-line development based on tolerability and efficacy, while no further development is planned for the HER2 cohort. 一项单独分析表明,在EGFR非典型突变病人中,反应强劲,包括内部反应率高。 A separate analysis showed strong responses in EGFR atypical mutation patients, including high intracranial response rates. 该公司将在2025年12月6日主办一次电话会议,讨论调查结果。 The company will host a conference call on December 6, 2025, to discuss findings.